Aurinia Pharmaceuticals Inc. — Director's Dealing 2021

Jan 4, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Aurinia Pharmaceuticals Inc. (AUPH)
CIK: 0001600620
Period of Report: 2021-01-01

Reporting Person: Huizinga Robert Bindert (Ex Vice President of Research)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	103592	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$2.63	2022-12-11	Common Stock (16000)		Direct
Stock Option (right to buy)	$3.02	2021-03-30	Common Stock (40000)		Direct
Stock Option (right to buy)	$3.20	2027-02-09	Common Stock (110000)		Direct
Stock Option (right to buy)	$5.30	2028-02-01	Common Stock (225000)		Direct
Stock Option (right to buy)	$6.06	2029-01-29	Common Stock (70000)		Direct
Stock Option (right to buy)	$18.38	2030-01-28	Common Stock (61100)		Direct
Stock Option (right to buy)	$13.03	2030-12-21	Common Stock (93593)		Direct

Footnotes

F1: The shares subject to the option are fully vested and immediately exercisable. They vested in three equal monthly installments from the grant date.

F2: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date.

F3: The shares subject to the option are fully vested and immediately exercisable. They vested in twelve equal monthly installments from the grant date.

F4: The shares subject to the option are fully vested and immediately exercisable. They vested in thirty-six equal monthly installments from the grant date.

F5: The shares subject to the option vest in thirty-six equal monthly installments from the grant date.

F6: The shares subject to the option vest in twenty-four equal monthly installments from the grant date.

F7: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.